Gabriel Lopez-Berestein - Publications

Affiliations: 
The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Molecular Biology, Oncology

293 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, ... ... Lopez-Berestein G, et al. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences. 25. PMID 38279277 DOI: 10.3390/ijms25021278  0.362
2023 Szymanowski W, Szymanowska A, Bielawska A, Lopez-Berestein G, Rodriguez-Aguayo C, Amero P. Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges. Cancers. 15. PMID 37958473 DOI: 10.3390/cancers15215300  0.307
2023 Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, et al. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. International Journal of Molecular Sciences. 24. PMID 36835335 DOI: 10.3390/ijms24043915  0.366
2020 Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. PMID 33149280 DOI: 10.1038/s41388-020-01517-3  0.36
2020 Elsayed AM, Amero P, Salama SA, Abdelaziz AH, Lopez-Berestein G, Rodriguez-Aguayo C. Back to the Future: Rethinking the Great Potential of lncRNA for Optimizing Chemotherapeutic Response in Ovarian Cancer. Cancers. 12. PMID 32854207 DOI: 10.3390/Cancers12092406  0.362
2020 Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget. 11: 2819-2833. PMID 32754300 DOI: 10.18632/Oncotarget.27667  0.426
2020 Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors. Molecular Cancer Therapeutics. PMID 32499298 DOI: 10.1158/1535-7163.Mct-19-0977  0.454
2020 Attia YM, Shouman SA, Salama SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. International Journal of Molecular Sciences. 21. PMID 32340192 DOI: 10.3390/Ijms21082974  0.466
2020 Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, ... ... Lopez-Berestein G, et al. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. Ebiomedicine. 52: 102630. PMID 31972470 DOI: 10.1016/J.Ebiom.2020.102630  0.329
2020 El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Signalling. 109539. PMID 31935430 DOI: 10.1016/J.Cellsig.2020.109539  0.452
2020 Ma S, Mangala LS, Hu W, Bayaktar E, Hu W, Jennings NB, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 6331: Cloaking VEGF in small extracellular vesicles as a cause of adaptive resistance to anti-VEGF therapy Cancer Research. 80: 6331-6331. DOI: 10.1158/1538-7445.Am2020-6331  0.354
2019 Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, et al. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Reports. 29: 4389-4406.e10. PMID 31875548 DOI: 10.1016/J.Celrep.2019.11.085  0.417
2019 Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. Rna Biology. 1-12. PMID 31847695 DOI: 10.1080/15476286.2019.1702283  0.401
2019 Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. The Journal of Clinical Investigation. PMID 31682236 DOI: 10.1172/Jci123396  0.389
2019 Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, ... Lopez-Berestein G, et al. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31391192 DOI: 10.1158/1078-0432.Ccr-18-3448  0.455
2019 Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, et al. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. PMID 31289363 DOI: 10.1038/S41388-019-0862-Y  0.378
2019 Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. PMID 31063534 DOI: 10.1093/Carcin/Bgz062  0.336
2019 Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, et al. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. PMID 30918328 DOI: 10.1038/S41388-019-0786-6  0.427
2019 Gonzalez-Villasana V, Rashed MH, Gonzalez-Cantú Y, Bayraktar R, Menchaca-Arredondo JL, Vazquez-Guillen JM, Rodriguez-Padilla C, Lopez-Berestein G, Resendez-Perez D. Presence of Circulating miR-145, miR-155, and miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors. Disease Markers. 2019: 6852917. PMID 30891102 DOI: 10.1155/2019/6852917  0.319
2019 Tekedereli I, Akar U, Alpay SN, Lopez-Berestein G, Ozpolat B. Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 38: 13-20. PMID 30806286 DOI: 10.1615/Jenvironpatholtoxicoloncol.2018027885  0.355
2019 Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, ... ... Lopez-Berestein G, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Ebiomedicine. PMID 30655206 DOI: 10.1016/J.Ebiom.2018.11.045  0.381
2019 Duzagac F, Lopez-Berestein G, Kanlikilicer P, Rodriguez-Aguoya C, Cardenas-Zuniga R, Guven U, Oktem G, Ozpolat B. Abstract 3686: Regulatory role cancer stem cells (CSCs)-derived exosomal miRNAs in ovarian cancer growth and progression Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3686  0.394
2019 Rodriguez-Aguayo C, Bayraktar E, Mangala LS, Ivan C, Lopez-Berestein G, Sood AK. Abstract 3579: Long non-coding RNA ADAMTS9-AS2 inhibits ovarian tumor growth via Annexin A1 Cancer Research. 79: 3579-3579. DOI: 10.1158/1538-7445.Sabcs18-3579  0.429
2019 Kanlikilicer P, El-Arabey AA, Denizli M, Bayraktar R, Ozpolat B, Lopez-Berestein G, Salama SA, Abd-Allah AR. Abstract 1981: M2-macrophage derived exosomes mediates tumor progression via GATA3-IL-4-IL-13 axis in ovarian cancer Cancer Research. 79: 1981-1981. DOI: 10.1158/1538-7445.Sabcs18-1981  0.39
2019 Ma S, McGuire MH, Stur E, Bayraktar E, Villar-Prados A, Wu SY, Yokoi A, Dasari SK, Rodriguez-Aguayo C, Liu J, Lopez-Berestein G, Sood AK. Abstract LB-311: Exosomal gain-of-function p53 protein promotes cancer-associated phenotype Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-311  0.429
2019 Mokhlis HA, Kahraman N, Baydogan S, Abdel-Aziz AH, Ashour A, Ivan C, Lopez-Berestein G, Ozpolat B. Abstract 4262: MiR-873 is the master regulator of autophagy genes through a novel negative feedback mechanism mediated by Elongation factor 2 kinase (eEF-2K) and suppresses tumor growth and progression of triple negative breast cancer Cancer Research. 79: 4262-4262. DOI: 10.1158/1538-7445.Am2019-4262  0.418
2019 Guven U, Mokhlis HA, Kahraman N, Ivan C, Duzagac F, Lopez-Berestein G, Oktem G, Ozpolat B. Abstract 2591: miR-193b is a novel regulator of Inhibition of Notch signaling by for targeting cancer stem cell and tumor microenvironment Cancer Research. 79: 2591-2591. DOI: 10.1158/1538-7445.Am2019-2591  0.466
2018 Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, ... ... Lopez-Berestein G, et al. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Molecular Therapy. Nucleic Acids. 14: 301-317. PMID 30654191 DOI: 10.1016/J.Omtn.2018.11.019  0.38
2018 Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Yang SM, Maloney DJ, et al. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Molecular Cancer Therapeutics. PMID 30420565 DOI: 10.1158/1535-7163.Mct-18-0365  0.343
2018 Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics. PMID 30305341 DOI: 10.1158/1535-7163.Mct-17-1050  0.425
2018 Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Artholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30084832 DOI: 10.1158/1078-0432.Ccr-18-0504  0.331
2018 Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, ... ... Lopez-Berestein G, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications. 9: 2923. PMID 30050129 DOI: 10.1038/S41467-018-04987-Y  0.459
2018 González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martin-Salvago MD, Luque RJ, ... ... Lopez-Berestein G, et al. Activating transcription factor 4 modulates TGFβ-induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30012564 DOI: 10.1158/1078-0432.Ccr-17-3125  0.391
2018 Kabil N, Bayraktar R, Kahraman N, Mokhlis HA, Calin GA, Lopez-Berestein G, Ozpolat B. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 29971628 DOI: 10.1007/S10549-018-4847-2  0.422
2018 Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, et al. Stress effects on FosB and interleukin-8 ()-driven ovarian cancer growth and metastasis. The Journal of Biological Chemistry. 293: 10041. PMID 29959278 DOI: 10.1074/Jbc.Aac118.004299  0.368
2018 Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Lopez-Berestein G, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. PMID 29809169 DOI: 10.1172/Jci122301  0.448
2018 Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil N, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong ST, Lopez-Berestein G, Calin GA, Ozpolat B. Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29748184 DOI: 10.1158/1078-0432.Ccr-17-1959  0.346
2018 Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, ... ... Lopez-Berestein G, et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Reports. 23: 823-837. PMID 29669287 DOI: 10.1016/J.Celrep.2018.03.078  0.444
2018 Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemerrle M, Gharpure KM, Rupaimoole R, Previs R, Wu SY, Pradeep S, Xu X, ... ... Lopez-Berestein G, et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Research. PMID 29661830 DOI: 10.1158/0008-5472.Can-16-1701  0.334
2018 Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, ... ... Lopez-Berestein G, et al. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications. 9: 476. PMID 29396402 DOI: 10.1038/S41467-017-02811-7  0.404
2018 Lara OD, Rodriquez-Aguayo C, Bayrakter E, Amero P, Mangala S, LaFargue C, Tari-Ashizawa A, Lopez-Berestein G, Sood A. Abstract 5786: Grabbing GRB2: The use of liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies Cancer Research. 78: 5786-5786. DOI: 10.1158/1538-7445.Am2018-5786  0.398
2018 Amero P, Rodriguez-Aguayo C, Lokesh G, Bayraktar E, Ivan C, Chaudhari R, Zhang S, Volk D, Sood A, Lopez-Berestein G. Development of novel modified aptamers to target Axl receptor in ovarian cancer Annals of Oncology. 29: iii17. DOI: 10.1093/Annonc/Mdy047.029  0.378
2017 Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. The Journal of Clinical Investigation. PMID 29251630 DOI: 10.1172/Jci95200  0.377
2017 Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, ... Lopez-Berestein G, et al. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. PMID 29249663 DOI: 10.1016/J.Stemcr.2017.11.010  0.451
2017 Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, ... ... Lopez-Berestein G, et al. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy. Nucleic Acids. 9: 251-262. PMID 29246304 DOI: 10.1016/J.Omtn.2017.06.023  0.48
2017 Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Reviews. PMID 29243000 DOI: 10.1007/S10555-017-9717-6  0.336
2017 Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, ... ... Lopez-Berestein G, et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports. 21: 2785-2795. PMID 29212026 DOI: 10.1016/J.Celrep.2017.11.020  0.357
2017 Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Demarzo A, Sood AK, Zhang L, Dang CV. MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Research. PMID 29180471 DOI: 10.1158/0008-5472.Can-17-0815  0.475
2017 Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, ... ... Lopez-Berestein G, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. The Journal of Clinical Investigation. PMID 29130936 DOI: 10.1172/Jci91553  0.397
2017 Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene. PMID 29059175 DOI: 10.1038/Onc.2017.348  0.431
2017 Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discovery. 3: 17029. PMID 28904816 DOI: 10.1038/celldisc.2017.29  0.32
2017 Sood AK, Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu S, Mangala LS, ... ... Lopez-Berestein G, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28855350 DOI: 10.1158/1078-0432.Ccr-17-0647  0.332
2017 Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications. 8: 310. PMID 28827520 DOI: 10.1038/S41467-017-00411-Z  0.408
2017 Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Lopez-Berestein G, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 2. PMID 28814667 DOI: 10.1172/Jci.Insight.93076  0.418
2017 Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Scientific Reports. 7: 3614. PMID 28620240 DOI: 10.1038/S41598-017-03972-7  0.335
2017 Hu Q, Hisamatsu T, Hammerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong ST, Sood AK, Afshar-Kharghan V. Role of platelet-derived Tgfβ1 in the progression of ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28611202 DOI: 10.1158/1078-0432.Ccr-16-3272  0.422
2017 Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, ... ... Lopez-Berestein G, et al. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology. 18: 98. PMID 28535802 DOI: 10.1186/S13059-017-1224-0  0.333
2017 Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, et al. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 27380-27392. PMID 28423708 DOI: 10.18632/Oncotarget.16068  0.394
2017 Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodriguez-Aguayo C, Lopez-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Molecular Cancer Therapeutics. PMID 28223424 DOI: 10.1158/1535-7163.Mct-16-0519  0.448
2017 Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, et al. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. Journal of Clinical Oncology. 35: TPS2604-TPS2604. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2604  0.44
2017 Ghazaly EA, Quesne JL, Jiang D, Mangala SL, Chettle J, Rodriguez-Aguayo C, Lopez-Berestein G, Gnanaranjan C, Mura M, Stavraka C, Sood AK, Blagden SP. Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-B30  0.448
2017 McGuire MH, Herbrich S, Wu S, Wang Y, Rupaimoole R, Yao H, Gharpure K, Lopez-Berestein G, Baggerly K, Sood A. Abstract 5377: Intragenic DNA methylation and increased gene expression: New directions from pan-cancer analysis Cancer Research. 77: 5377-5377. DOI: 10.1158/1538-7445.Am2017-5377  0.338
2017 Ashizawa AT, Gutierrez-Puente Y, Ford R, Lopez-Berestein G. Abstract 5091: Activity of Bcl-2 antisense therapeutic in aggressive non-Hodgkin's lymphoma Cancer Research. 77: 5091-5091. DOI: 10.1158/1538-7445.Am2017-5091  0.328
2017 Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Noh K, Filant J, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Bartholomeusz GA, ... ... Lopez-Berestein G, et al. Abstract 473: PRKRA/PACT expression promotes chemoresistance in mucinous ovarian cancer Cancer Research. 77: 473-473. DOI: 10.1158/1538-7445.Am2017-473  0.444
2017 Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Dorniak PL, ... ... Lopez-Berestein G, et al. Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers Cancer Research. 77: 4144-4144. DOI: 10.1158/1538-7445.Am2017-4144  0.458
2017 Yang H, Zhang S, Mao W, Ahmed AA, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Le X, Lu Z, Bast RC. Abstract 3564: Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts Cancer Research. 77: 3564-3564. DOI: 10.1158/1538-7445.Am2017-3564  0.395
2017 Bayraktar E, Rodriguez-Aguayo C, Siddik Z, Lopez-Berestein G. Abstract 2066: Delivery of 2`F-PS2 PTGER3 siRNA-DOPC enhances anti-tumoral activity in cisplatin resistant ovarian cancer model Cancer Research. 77: 2066-2066. DOI: 10.1158/1538-7445.Am2017-2066  0.387
2017 Kanlikilicer P, Bayraktar R, Rashed M, Aslan B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 1988: Exosome-mediated ovarian cancer tumorigenesis mediated by miR1246/Rb/Cav1 axis Cancer Research. 77: 1988-1988. DOI: 10.1158/1538-7445.Am2017-1988  0.363
2017 Asik E, Kahraman N, Guray T, Volkan M, Lopez-Berestein G, Ozpolat B. Abstract 1125: Eukaryotic Elongation Factor 2 Kinase (eEF-2K) is a novel therapeutic target in BRCA1+ mutated breast cancer Cancer Research. 77: 1125-1125. DOI: 10.1158/1538-7445.Am2017-1125  0.449
2016 Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. PMID 28036267 DOI: 10.18632/Oncotarget.14264  0.439
2016 Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis R, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, ... ... Lopez-Berestein G, et al. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27903673 DOI: 10.1158/1078-0432.Ccr-16-1025  0.344
2016 Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, ... ... Lopez-Berestein G, et al. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24: 685-700. PMID 27829138 DOI: 10.1016/J.Cmet.2016.10.011  0.459
2016 Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, ... ... Lopez-Berestein G, et al. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17: 1621-1631. PMID 27806300 DOI: 10.1016/J.Celrep.2016.10.020  0.433
2016 Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, ... ... Lopez-Berestein G, et al. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. Jci Insight. 1: e87754. PMID 27777972 DOI: 10.1172/Jci.Insight.87754  0.4
2016 Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, ... Lopez-Berestein G, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research. PMID 27742688 DOI: 10.1158/0008-5472.Can-16-0714  0.434
2016 Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer - An Emerging Concept. Ebiomedicine. PMID 27720213 DOI: 10.1016/J.Ebiom.2016.09.017  0.343
2016 Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene. PMID 27669434 DOI: 10.1038/Onc.2016.308  0.338
2016 Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, Fielding B, Sood AK, Harris AL. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. PMID 27568980 DOI: 10.1038/Onc.2016.256  0.329
2016 Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, ... Lopez-Berestein G, et al. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. PMID 27478041 DOI: 10.1016/J.Ccell.2016.06.020  0.443
2016 Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, et al. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 29: 874-888. PMID 27300436 DOI: 10.1016/J.Ccell.2016.04.016  0.379
2016 Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, et al. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. PMID 27160903 DOI: 10.1016/J.Celrep.2016.04.034  0.459
2016 Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, ... ... Lopez-Berestein G, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. The Journal of Clinical Investigation. PMID 27064283 DOI: 10.1172/Jci85086  0.383
2016 Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7: 11169. PMID 27041221 DOI: 10.1038/Ncomms11169  0.337
2016 Rytelewski M, Vareki SM, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. PMID 26959114 DOI: 10.18632/Oncotarget.7883  0.412
2016 Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. PMID 26918603 DOI: 10.18632/Oncotarget.7618  0.33
2016 Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery. 6: 235-46. PMID 26865249 DOI: 10.1158/2159-8290.Cd-15-0893  0.373
2016 Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. 35: 801. PMID 26865225 DOI: 10.1038/Onc.2015.177  0.357
2016 Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Molecular Cancer Therapeutics. PMID 26861249 DOI: 10.1158/1535-7163.Mct-15-0733-T  0.359
2016 Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, ... ... Lopez-Berestein G, et al. Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108. PMID 26819345 DOI: 10.1093/Jnci/Djv426  0.374
2016 Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, ... ... Lopez-Berestein G, et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. PMID 26725326 DOI: 10.1038/Onc.2015.492  0.391
2016 Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods in Molecular Biology (Clifton, N.J.). 1402: 189-97. PMID 26721492 DOI: 10.1007/978-1-4939-3378-5_15  0.404
2016 Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods in Molecular Biology (Clifton, N.J.). 1402: 33-41. PMID 26721482 DOI: 10.1007/978-1-4939-3378-5_5  0.319
2016 Pradeep S, Huang J, Mora E, Wu SY, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract B68: Erythropoietin stimulates ovarian tumor growth via EphB4. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B68  0.444
2016 Kanlikilicer P, Rashed MMHS, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Cristian R, Bayraktar E, Picher M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 763: Exosomal miR-6126 as a novel tumor suppressor in ovarian cancer Cancer Research. 76: 763-763. DOI: 10.1158/1538-7445.Am2016-763  0.448
2016 Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi H, Stone RL, Cho MS, Nick AM, Lopez-Berestein G, Afshar-Khargan V, Sood AK. Abstract 5048: Platelet FAK is a critical regulator of tumor growth after withdrawal of anti-angiogenic therapy Cancer Research. 76: 5048-5048. DOI: 10.1158/1538-7445.Am2016-5048  0.383
2016 Bayraktar E, Rodriguez-Aguayo C, Mai J, Ivan C, Chavez-Reyes A, Sood AK, Ferrari M, Shen H, Lopez-Berestein G. Abstract 4668: Silencing PTGER3 enhances chemotherapeutic responses Cancer Research. 76: 4668-4668. DOI: 10.1158/1538-7445.Am2016-4668  0.507
2016 Wagner MJ, Mitra R, Baze W, Barnhart K, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 2094: Translating EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA) to the clinic Cancer Research. 76: 2094-2094. DOI: 10.1158/1538-7445.Am2016-2094  0.315
2016 Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Zhang X, Wistuba I, Lopez-Berestein G, Fabbri M, Calin G. Targeting miR-155 to resensitize lung cancer to chemotherapy European Journal of Cancer. 61: S116. DOI: 10.1016/S0959-8049(16)61409-0  0.336
2015 Bullock MD, Silva AM, Kanlikilicer-Unaldi P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA. Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Non-Coding Rna. 1: 53-68. PMID 29861415 DOI: 10.3390/Ncrna1010053  0.388
2015 Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... ... Lopez-Berestein G, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047  0.471
2015 Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology (Baltimore, Md.). PMID 26599259 DOI: 10.1002/Hep.28367  0.324
2015 Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram PT, Sehgal V, Lopez-Berestein G, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26581245 DOI: 10.1158/1078-0432.Ccr-15-1275  0.397
2015 Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, ... ... Lopez-Berestein G, et al. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. PMID 26481148 DOI: 10.1016/J.Ccell.2015.09.008  0.454
2015 Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, ... Lopez-Berestein G, et al. YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma. Hepatology (Baltimore, Md.). PMID 26389641 DOI: 10.1002/Hep.28223  0.381
2015 Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of MiRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. PMID 26313360 DOI: 10.18632/Oncotarget.4971  0.373
2015 Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, ... ... Lopez-Berestein G, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. PMID 26257064 DOI: 10.1038/Onc.2015.302  0.444
2015 Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, ... Lopez-Berestein G, et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. PMID 26212011 DOI: 10.1038/Onc.2015.279  0.428
2015 Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: Future of Oncotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3121-30. PMID 26180057 DOI: 10.1158/1078-0432.Ccr-14-1189  0.356
2015 Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, et al. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. Plos One. 10: e0131833. PMID 26146988 DOI: 10.1371/Journal.Pone.0131833  0.477
2015 Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, ... ... Lopez-Berestein G, et al. The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6: 7351. PMID 26081979 DOI: 10.1038/Ncomms8351  0.451
2015 Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. Journal of the National Cancer Institute. 107. PMID 25995442 DOI: 10.1093/Jnci/Djv108  0.391
2015 Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520: 697-701. PMID 25901683 DOI: 10.1038/Nature14418  0.444
2015 Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, ... ... Lopez-Berestein G, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 6: 4266-73. PMID 25738355 DOI: 10.18632/Oncotarget.2887  0.374
2015 Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. PMID 25639871 DOI: 10.1038/Onc.2014.469  0.396
2015 Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, ... ... Lopez-Berestein G, et al. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2127-37. PMID 25595279 DOI: 10.1158/1078-0432.Ccr-14-2279  0.392
2015 Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. The Journal of Pathology. 235: 25-36. PMID 25230372 DOI: 10.1002/Path.4443  0.344
2015 Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang T, Xie X, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Abstract P6-17-01: MicroRNA-34a suppresses breast cancer bone metastasis by inhibiting osteoclastogenesis and targeting tgif2 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-17-01  0.336
2015 Wu SY, Filant J, McGuire M, Rupaimoole R, Pradeep S, Unruh A, Shelley H, Ivan C, Dennis R, Rodriguez-Aguayo C, Sehgal V, Miyake T, Nagaraja A, Gharpure K, Armaiz G, ... ... Lopez-Berestein G, et al. Abstract 5466: Integrative TCGA analyses identify Basonuclin1 (BNC1) as a key mediator for platinum resistance Cancer Research. 75: 5466-5466. DOI: 10.1158/1538-7445.Am2015-5466  0.467
2015 Napoli M, Venkatanarayan A, Raulji P, Abbas HA, Norton W, Sood AK, Lopez-Berestein G, Tsai KY, Coarfa C, Gunaratne PH, Flores ER. Abstract 3975: Pharmacologic inhibition of the ΔNp63/DGCR8 axis as a novel therapeutic strategy for p53-deficient and mutant tumors Cancer Research. 75: 3975-3975. DOI: 10.1158/1538-7445.Am2015-3975  0.404
2015 Ashour A, Erdogan A, Alpay SN, Kahraman N, Yuka E, Lopez-Berestein G, Ozpolat B. Abstract 2642: EF2-kinase (EF2K): A novel molecular target in ovarian and pancreatic cancers Cancer Research. 75: 2642-2642. DOI: 10.1158/1538-7445.Am2015-2642  0.491
2015 Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Dorniak P, Previs R, Sadaoui N, Stone R, Matsuo K, Dalton HJ, Lutgendorf SK, Sood AK, Lopez-Berestein G. Abstract 2359: Adrenergic regulation of MCP-1 leads to enhanced macrophage recruitment and ovarian carcinoma growth Cancer Research. 75: 2359-2359. DOI: 10.1158/1538-7445.Am2015-2359  0.403
2015 Gharpure KM, Tucker SL, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, et al. Abstract 2273: Mechanistic and functional implications of FABP4 in ovarian cancer metastasis Cancer Research. 75: 2273-2273. DOI: 10.1158/1538-7445.Am2015-2273  0.448
2015 Pradeep S, Huang J, Mora E, Nick A, Cho M, Wu S, Rupaimoole R, Xiong C, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract 1952: Adverse effects of erythropoietin stimulates tumor growth via EphB4 Cancer Research. 75: 1952-1952. DOI: 10.1158/1538-7445.Am2015-1952  0.436
2015 Rupaimole R, Previs R, Lee J, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison J, Rodriguez-Aguayo C, Calin GA, Mills G, Zhang W, Lopez-Berestein G, Bhattacharya P, Sood AK. Abstract 142: SiRNA therapy against novel lncRNA NRCP: shutting down the fuel for cancer cells Cancer Research. 75: 142-142. DOI: 10.1158/1538-7445.Am2015-142  0.384
2015 Zand B, Previs R, Zacharias N, Rupaimoole R, Dalton H, Hansen J, Rodriguez-Aguayo C, Guindani M, Lopez-Berestein G, Bhattacharya P, Sood A. Role of increased n-acetylaspartate levels in epithelial ovarian cancer Gynecologic Oncology. 137: 68. DOI: 10.1016/J.Ygyno.2015.01.161  0.365
2014 Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, ... ... Lopez-Berestein G, et al. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 26: 863-79. PMID 25490449 DOI: 10.1016/J.Ccell.2014.10.010  0.349
2014 Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications. 5: 5671. PMID 25476932 DOI: 10.1038/Ncomms6671  0.358
2014 Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, ... ... Lopez-Berestein G, et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications. 5: 5202. PMID 25351346 DOI: 10.1038/Ncomms6202  0.31
2014 Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, ... ... Lopez-Berestein G, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Molecular Cancer Therapeutics. 13: 2876-85. PMID 25281617 DOI: 10.1158/1535-7163.Mct-14-0074  0.454
2014 Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications. 5: 5092. PMID 25277212 DOI: 10.1038/Ncomms6092  0.442
2014 Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, ... ... Lopez-Berestein G, et al. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics. 13: 2583-94. PMID 25193509 DOI: 10.1158/1535-7163.Mct-14-0028  0.399
2014 Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 26: 77-91. PMID 25026212 DOI: 10.1016/J.Ccr.2014.05.002  0.437
2014 Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Science Translational Medicine. 6: 240ps7. PMID 24920658 DOI: 10.1126/Scitranslmed.3008362  0.348
2014 Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology & Therapy. 15: 1061-7. PMID 24841852 DOI: 10.4161/Cbt.29184  0.315
2014 Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology. 10: 728. PMID 24799285 DOI: 10.1002/Msb.20134892  0.373
2014 Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3280-8. PMID 24756370 DOI: 10.1158/1078-0432.Ccr-14-0445  0.317
2014 Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, et al. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biology & Therapy. 15: 919-29. PMID 24755674 DOI: 10.4161/Cbt.28882  0.409
2014 Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, et al. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Molecular Cancer Therapeutics. 13: 1750-7. PMID 24755199 DOI: 10.1158/1535-7163.Mct-13-0930  0.402
2014 Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, ... ... Lopez-Berestein G, et al. Notch3 pathway alterations in ovarian cancer. Cancer Research. 74: 3282-93. PMID 24743243 DOI: 10.1158/0008-5472.Can-13-2066  0.431
2014 Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, ... ... Lopez-Berestein G, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Reports. 7: 488-500. PMID 24703838 DOI: 10.1016/J.Celrep.2014.03.009  0.442
2014 Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Lopez-Berestein G, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/Ncomms4459  0.388
2014 Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, ... Lopez-Berestein G, et al. Autocrine effects of tumor-derived complement. Cell Reports. 6: 1085-95. PMID 24613353 DOI: 10.1016/J.Celrep.2014.02.014  0.451
2014 Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Research. 74: 1287-93. PMID 24556724 DOI: 10.1158/0008-5472.Can-13-2825  0.371
2014 Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. Journal of Liposome Research. 24: 182-90. PMID 24443972 DOI: 10.3109/08982104.2013.863208  0.327
2014 Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Advanced Drug Delivery Reviews. 66: 110-6. PMID 24384374 DOI: 10.1016/J.Addr.2013.12.008  0.306
2014 Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 35: 1100-9. PMID 24379240 DOI: 10.1093/Carcin/Bgt489  0.457
2014 Pecot C, Wu S, Bellister S, Bhattacharya R, Maharaj A, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Lopez-Berestein G, Ellis LM, Sood A. Abstract B47: Therapeutic KRAS silencing in lung and colon cancer models Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B47  0.445
2014 Gharpure KM, Chu KS, Bowerman C, Miyake T, Pradeep S, Mangala LS, Han H, Rupaimoole R, Wu SY, Dalton HJ, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Abstract 5403: Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer Cancer Research. 74: 5403-5403. DOI: 10.1158/1538-7445.Am2014-5403  0.367
2014 Jiang D, Mangala LS, Wang H, Wu S, Rao LG, Rodriguez-Aguayo C, Pradeep S, Volk DE, Lopez-Berestein G, Sood AK. Abstract 4468: Tumor vasculature targeting using cell-specific thioaptamer decorated chitosan nanoparticle Cancer Research. 74: 4468-4468. DOI: 10.1158/1538-7445.Am2014-4468  0.403
2014 Rupaimoole R, Ivan C, Pecot C, Wu S, Pradeep S, Zand B, Nagaraja A, Gharpure K, Dalton H, Sadaoui N, Zhang W, Lopez-Berestein G, Sood A. Abstract 3532: Hypoxia is a master regulator of Drosha- and Dicer-dependent miRNA biogenesis in cancer Cancer Research. 74: 3532-3532. DOI: 10.1158/1538-7445.Am2014-3532  0.387
2014 Gonzalez-Villasana V, Rodriguez-Aguayo C, Fuentes-Mattei E, Pradeep S, Ivan C, Sood AK, Lopez-Berestein G. Abstract 2992: Zoledronic acid inhibits angiogenesis through Rac1 inactivation in ovarian cancer Cancer Research. 74: 2992-2992. DOI: 10.1158/1538-7445.Am2014-2992  0.443
2014 Dalton HJ, Reusser NM, Zien A, Jackson D, Previs R, Rupaimoole R, Zand B, Lopez-Berestein G, Coleman RL, Sood AK. Abstract 2983: Bisphosphonates: New strategies for targeting angiogenesis in ovarian cancer Cancer Research. 74: 2983-2983. DOI: 10.1158/1538-7445.Am2014-2983  0.463
2014 Dalton HJ, Pradeep S, Armaiz-Pena GN, Previs R, Davis A, Rupaimoole R, Zand B, Hailemichael Y, Overwijk WW, Lopez-Berestein G, Sood AK. Abstract 2982: Macrophages modulate adaptive resistance to anti-angiogenic therapy Cancer Research. 74: 2982-2982. DOI: 10.1158/1538-7445.Am2014-2982  0.389
2014 Armaiz-Pena GN, Nagaraja AS, Allen JK, Sadaoui NC, Rupaimoole R, wu sY, Pradeep S, Han HD, Zand B, Dalton H, Previs R, Taylor M, Bottsford-Miller J, Mangala LS, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. Abstract 1062: Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction Cancer Research. 74: 1062-1062. DOI: 10.1158/1538-7445.Am2014-1062  0.387
2014 Hu W, Liu T, Ivan C, Huang J, Dalton H, Previs R, Nick A, Lopez-Berestein G, Coleman R, Sood A. Selective activation of Notch3 in high-grade serous ovarian cancer Gynecologic Oncology. 133: 115. DOI: 10.1016/J.Ygyno.2014.03.304  0.372
2013 Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. Plos One. 8: e79167. PMID 24236104 DOI: 10.1371/Journal.Pone.0079167  0.451
2013 Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. Journal of Drug Targeting. 21: 904-13. PMID 24079419 DOI: 10.3109/1061186X.2013.837469  0.391
2013 Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Molecular Therapy. Nucleic Acids. 2: e121. PMID 24022053 DOI: 10.1038/Mtna.2013.45  0.447
2013 Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, ... ... Lopez-Berestein G, et al. Tumour angiogenesis regulation by the miR-200 family. Nature Communications. 4: 2427. PMID 24018975 DOI: 10.1038/Ncomms3427  0.36
2013 Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, ... ... Lopez-Berestein G, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery. 3: 1302-15. PMID 24002999 DOI: 10.1158/2159-8290.Cd-13-0159  0.404
2013 Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 24: 229-41. PMID 23871637 DOI: 10.1016/J.Ccr.2013.06.004  0.397
2013 Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, ... Lopez-Berestein G, et al. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E2572-81. PMID 23798432 DOI: 10.1073/Pnas.1304318110  0.393
2013 Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Lopez-Berestein G, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. 123: 2119-30. PMID 23585472 DOI: 10.1172/JCI65425  0.34
2013 Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 23: 186-99. PMID 23410973 DOI: 10.1016/J.Ccr.2012.12.020  0.348
2013 Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology (Baltimore, Md.). 58: 182-91. PMID 23389994 DOI: 10.1002/Hep.26310  0.385
2013 Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, ... ... Lopez-Berestein G, et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1806-15. PMID 23386691 DOI: 10.1158/1078-0432.Ccr-12-2764  0.425
2013 Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, ... ... Lopez-Berestein G, et al. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nature Communications. 4: 1403. PMID 23360994 DOI: 10.1038/Ncomms2413  0.394
2013 Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 809-20. PMID 23344261 DOI: 10.1158/1078-0432.Ccr-12-2736  0.42
2013 Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecologic Oncology. 128: 506-11. PMID 23200915 DOI: 10.1016/J.Ygyno.2012.11.029  0.391
2013 Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 170-82. PMID 23147994 DOI: 10.1158/1078-0432.Ccr-12-1045  0.478
2013 Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Letters. 330: 123-9. PMID 22776561 DOI: 10.1016/J.Canlet.2012.07.001  0.451
2013 Moreno-Smith M, Halder J, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Lopez-Berestein G, et al. ATP11B mediates platinum resistance in ovarian cancer Journal of Clinical Investigation. 123: 5411-5411. DOI: 10.1172/Jci73904  0.379
2013 Zhang S, Mao W, Sood AK, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Li Z, Bast RC, Le X. Abstract 5433: Knockdown of the glycolytic enzyme PFKFB2 induces growth inhibition and enhances paclitaxel sensitivity in ovarian cancer cells. Cancer Research. 73: 5433-5433. DOI: 10.1158/1538-7445.Am2013-5433  0.463
2013 Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Deng D, Fuentes-Mattei E, Hwang RF, Wang H, Pena GNA, Aslan B, Gutierrez-Puente Y, Sood AK, Logsdon C, Lopez-Berestein G. Abstract 4959: Targeting pancreatic stellate cells (PSC) to treat pancreatic cancer. Cancer Research. 73: 4959-4959. DOI: 10.1158/1538-7445.Am2013-4959  0.456
2013 Rodriguez-Aguayo C, Shen H, Gonzalez-Villasana V, Zhang G, Deng X, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han H, Sood AK, Ferrari M, Lopez-Berestein G. Abstract 3269: Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery . Cancer Research. 73: 3269-3269. DOI: 10.1158/1538-7445.Am2013-3269  0.435
2013 Wu SY, Unruh AK, Rupaimoole R, Ivan C, Ruder D, Pradeep S, Sehgal V, Rodriguez-Aguayo C, Pecot C, Miyake T, Lopez-Berestein G, Ram P, Baggerly KA, Sood AK. Abstract 2036: Overcoming platinum-resistance in ovarian cancer via targeting basonuclin1 (BNC1). Cancer Research. 73: 2036-2036. DOI: 10.1158/1538-7445.Am2013-2036  0.456
2013 Hu W, Ivan C, Bottsford-Miller J, Zand B, Dalton H, Nick A, Lopez-Berestein G, Coleman R, Bagglerly K, Sood A. Comprehensive epigenetic analysis of Notch pathway in high-grade serous ovarian cancer Gynecologic Oncology. 130: e115. DOI: 10.1016/J.Ygyno.2013.04.333  0.39
2013 Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, et al. Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer [Cancer Cell 23 (2013) 186-199] Cancer Cell. 23. DOI: 10.1016/J.Ccr.2013.04.029  0.411
2012 Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6648-57. PMID 23052253 DOI: 10.1158/1078-0432.Ccr-12-2715  0.374
2012 Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. Plos One. 7: e41171. PMID 22911754 DOI: 10.1371/Journal.Pone.0041171  0.452
2012 Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Research : Bcr. 14: R108. PMID 22812534 DOI: 10.1186/Bcr3229  0.368
2012 Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 33: 1843-53. PMID 22581827 DOI: 10.1093/Carcin/Bgs167  0.426
2012 Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Human Pathology. 43: 1638-44. PMID 22436627 DOI: 10.1016/J.Humpath.2011.12.004  0.404
2012 Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, ... ... Lopez-Berestein G, et al. Paraneoplastic thrombocytosis in ovarian cancer. The New England Journal of Medicine. 366: 610-8. PMID 22335738 DOI: 10.1056/Nejmoa1110352  0.404
2012 Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Erratum to: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer Breast Cancer Research. 14. DOI: 10.1186/Bcr3370  0.344
2012 Wu SY, Unruh AK, Bartholomeusz G, Ivan C, Pecot CV, Rupaimoole R, Han H, Bottsford-Miller J, Tucker SL, Coleman RL, Lopez-Berestein G, Baggerly KA, Sood AK. Abstract 884: Basonuclin1 (BNC1): A novel therapeutic target in ovarian cancer identified through integrative TCGA-based functional genomic analysis Cancer Research. 72: 884-884. DOI: 10.1158/1538-7445.Am2012-884  0.439
2012 Vathipadiekal V, Ozbun L, Lee J, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Mok SC, Birrer MJ. Abstract 5057: Gene expression profile of chemoresponse of microdissected papillary serous tumors of the ovary identifies POLH and REV3L as potential therapeutic targets Cancer Research. 72: 5057-5057. DOI: 10.1158/1538-7445.Am2012-5057  0.461
2012 Park Y, Jung SY, Rodriguez-Aguayo C, Peng G, Lee S, Kim SB, Kim K, Leem S, Lin S, Lopez-Berestein G, Sood AK, Lee J. Abstract 2962: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair Cancer Research. 72: 2962-2962. DOI: 10.1158/1538-7445.Am2012-2962  0.431
2011 Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinal cancer cell lines. Plos One. 6: e23208. PMID 22028766 DOI: 10.1371/Journal.Pone.0023208  0.481
2011 Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, ... ... Lopez-Berestein G, et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. Journal of the National Cancer Institute. 103: 1596-612. PMID 21957230 DOI: 10.1093/Jnci/Djr372  0.314
2011 Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 141: 1728-37. PMID 21806944 DOI: 10.1053/J.Gastro.2011.07.037  0.416
2011 Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, ... ... Lopez-Berestein G, et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Research. 71: 6030-9. PMID 21795478 DOI: 10.1158/0008-5472.Can-10-2719  0.326
2011 Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, ... ... Lopez-Berestein G, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. Plos One. 6: e21121. PMID 21754983 DOI: 10.1371/Journal.Pone.0021121  0.479
2011 Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5674-85. PMID 21753153 DOI: 10.1158/1078-0432.Ccr-11-0432  0.386
2011 Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3716-26. PMID 21512144 DOI: 10.1158/1078-0432.Ccr-11-0233  0.387
2011 Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. Plos One. 6: e17918. PMID 21445297 DOI: 10.1371/Journal.Pone.0017918  0.466
2011 Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2250-9. PMID 21421858 DOI: 10.1158/1078-0432.Ccr-10-2718  0.441
2011 Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, et al. Functional roles of Src and Fgr in ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1713-21. PMID 21300758 DOI: 10.1158/1078-0432.Ccr-10-2081  0.456
2011 Pena GNA, Stone RL, Nick AM, Villares GJ, Cruz A, Vivas-Mejias P, Wu Z, English RD, Soman KV, Deavers MT, Zien A, Soldatos T, Jackson DB, Wiktorowicz JE, Torres-Lugo M, ... ... Lopez-Berestein G, et al. Abstract 937: Molecular dynamics of SrcS17 activation in chronic stress-induced tumor growth Cancer Research. 71: 937-937. DOI: 10.1158/1538-7445.Am2011-937  0.419
2011 Alpay N, Tekedereli I, Lopez-Berestein G, Dalby K, Ozpolat B. Abstract 3787: Serotonin signaling plays a role in regulation of autophagy in breast cancer cells Cancer Research. 71: 3787-3787. DOI: 10.1158/1538-7445.Am2011-3787  0.427
2011 Rodriguez-Aguayo C, Vivas-Mejia PE, Han H, Shahzad MMK, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Abstract 1735: Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer Cancer Research. 71: 1735-1735. DOI: 10.1158/1538-7445.Am2011-1735  0.444
2011 Bradley AT, Zheng H, Ziebarth A, Sakati W, Eier S, Lopez-Berestein G, Sood AK, Landen C, Eblen ST. Abstract 1649: The E3 ubiquitin ligase EDD regulates platinum resistance and is a novel therapeutic target for epithelial ovarian cancer Cancer Research. 71: 1649-1649. DOI: 10.1158/1538-7445.Am2011-1649  0.469
2011 Mora EM, Pecot CV, Nick AM, Mangala LS, Han HD, Stein MA, Brock S, Vivas-Mejias P, Sung B, Nishimura M, Matsuo K, Kannan S, Zweidler-McKay PA, Armaiz-Pena GN, Shahzad MMK, ... ... Lopez-Berestein G, et al. Abstract 1618: Erythropoietin meets a new receptor Cancer Research. 71: 1618-1618. DOI: 10.1158/1538-7445.Am2011-1618  0.435
2011 Gonzalez-Villasana V, Nieves-Alicea R, McMurtry V, Huaringa A, Simeone A, Gutierrez-Puente Y, Lopez-Berestein G, Tari AM. Abstract 1426: Cyclooxygenase-2 (COX-2) utilizes Jun N-terminal kinases to induce invasion but not tamoxifen resistance in MCF-7 breast cancer cells Cancer Research. 71: 1426-1426. DOI: 10.1158/1538-7445.Am2011-1426  0.442
2011 Ziebarth A, Zheng H, Bradley A, Sakati W, Eier S, Lopez-Berestein G, Sood A, Eblen S, Landen C. The ubiquitin ligase EDD mediates platinum resistance and is a target for therapy in epithelial ovarian cancer Gynecologic Oncology. 120: S26-S27. DOI: 10.1016/J.Ygyno.2010.12.066  0.392
2010 Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics. 9: 3186-99. PMID 20889728 DOI: 10.1158/1535-7163.Mct-10-0563  0.468
2010 Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocrine-Related Cancer. 17: 1021-33. PMID 20861284 DOI: 10.1677/Erc-10-0073  0.442
2010 Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. The Journal of Biological Chemistry. 285: 35462-70. PMID 20826776 DOI: 10.1074/Jbc.M110.109579  0.329
2010 Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 18: 109-21. PMID 20708153 DOI: 10.1016/J.Ccr.2010.06.018  0.425
2010 Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Molecular Cancer Therapeutics. 9: 1180-7. PMID 20423989 DOI: 10.1158/1535-7163.Mct-09-1025  0.453
2010 Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, ... ... Lopez-Berestein G, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. The Journal of Clinical Investigation. 120: 1515-23. PMID 20389021 DOI: 10.1172/Jci40802  0.45
2010 Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 6: 322-9. PMID 20224296 DOI: 10.4161/Auto.6.3.11625  0.452
2010 Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, ... ... Lopez-Berestein G, et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 184-94. PMID 20028751 DOI: 10.1158/1078-0432.Ccr-09-1180  0.478
2010 Tanaka T, Lingegowda M, Nieves-Alicea R, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Ferrari M. Abstract LB-143: Sustained siRNA delivery by mesoporous silicon particles Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-143  0.416
2010 Tekedereli I, Lopez-Berestein G, Ozpolat B. Abstract 88: Targeting Bcl-XL enhances arsenic-induced cell death in ovarian cancer cells Cancer Research. 70: 88-88. DOI: 10.1158/1538-7445.Am10-88  0.445
2010 Vivas PE, Rodríguez-Aguayo C, Han H, Shahzad MM, Sood AK, Lopez-Berestein G. Abstract 677: Targeting the survivin splice variant 2β in taxane-resistant ovarian cancer Cancer Research. 70: 677-677. DOI: 10.1158/1538-7445.Am10-677  0.441
2010 Shahzad MM, Mangala LS, Lee JW, Matsuo K, Nair MP, Han HD, Mora EM, Lu C, Gaur P, Haghpeykar SB, Carroll AR, Stone RL, Lopez-Berestein G, Lacko AG, Sood AK. Abstract 5517: Targeting anticancer therapeutics: A role for reconstituted high density lipoprotein (rHDL) Cancer Research. 70: 5517-5517. DOI: 10.1158/1538-7445.Am10-5517  0.437
2010 Rodriguez-Aguayo C, Vivas-Mejia P, Benito JM, Fernandez A, Francois-Xavier C, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Abstract 5468: JNK-1 inhibition leads to antitumor activity in ovarian cancer Cancer Research. 70: 5468-5468. DOI: 10.1158/1538-7445.Am10-5468  0.497
2010 Ozpolat B, Tekedereli I, Akar U, Lopez-Berestein G. Abstract 5108: Silencing of Bcl-2 by liposomal siRNA enhances Doxorubicin-induced autophagy and inhibits in vivo tumor growth of ER(−) and ER(−) breast cancers Cancer Research. 70: 5108-5108. DOI: 10.1158/1538-7445.Am10-5108  0.455
2010 Landen CN, Goodman B, Nick AM, Stone RL, Meijia PV, Miller LD, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer Cancer Research. 70: 4288-4288. DOI: 10.1158/1538-7445.Am10-4288  0.496
2010 Chakravarty D, Challa R, Dandamudi R, Vivas-Mejia P, Lopez-Berestein G, Tekmal RR, Sood AK, Vadlamudi RK. Abstract 3669: PELP1: A novel therapeutic target for ovarian cancer progression and metastasis Cancer Research. 70: 3669-3669. DOI: 10.1158/1538-7445.Am10-3669  0.502
2010 Carroll A, Kim SW, Nick AM, Stone RL, Spannuth WA, Armaiz-Pena GN, Matsuo K, Vivas-Mejia PE, Mangala S, Mora EM, Shahzad M, Lopez-Berestein G, Sood AK. Abstract 1811: Breaking scaffolds: Targeting paxillin in ovarian cancer Cancer Research. 70: 1811-1811. DOI: 10.1158/1538-7445.Am10-1811  0.503
2010 Nick AM, Stone RL, Spannuth WA, Landen CN, Villares G, Armaiz-Pena G, Carroll AR, Ozpolat B, Tekedereli I, Vivas-Mejia P, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 1044: Silencing p130cas in ovarian carcinoma induces autophagic cell death Cancer Research. 70: 1044-1044. DOI: 10.1158/1538-7445.Am10-1044  0.459
2009 Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. Plos One. 4: e7502. PMID 19847298 DOI: 10.1371/Journal.Pone.0007502  0.45
2009 Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 148-52. PMID 19805003 DOI: 10.1016/J.Drup.2009.09.001  0.395
2009 Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. Methods of Molecular Biology. 555: 29-42. PMID 19495686 DOI: 10.1007/978-1-60327-295-7_3  0.376
2009 Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, ... ... Lopez-Berestein G, et al. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3770-80. PMID 19470734 DOI: 10.1158/1078-0432.Ccr-08-2306  0.32
2009 Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. International Journal of Cancer. 125: 264-75. PMID 19408305 DOI: 10.1002/Ijc.24341  0.322
2009 Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biology & Therapy. 8: 1027-34. PMID 19395869 DOI: 10.4161/Cbt.8.11.8523  0.405
2009 Armaiz-Pena G, Villares G, Han L, Lin Y, Sanguino A, Deavers M, Gallick G, Bar-Eli M, Lopez-Berestein G, Cole S, Lutgendorf S, Sood A. 5. Molecular mechanisms of Src activation in chronic stress-induced cancer growth Brain, Behavior, and Immunity. 23: S26. DOI: 10.1016/J.Bbi.2009.06.010  0.343
2008 Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, ... ... Lopez-Berestein G, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. The New England Journal of Medicine. 359: 2641-50. PMID 19092150 DOI: 10.1056/Nejmoa0803785  0.376
2008 Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8143-51. PMID 19088029 DOI: 10.1158/1078-0432.Ccr-08-1539  0.433
2008 Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Research. 68: 9078-86. PMID 18974154 DOI: 10.1158/0008-5472.Can-08-2397  0.392
2008 Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 27: 7192-200. PMID 18806828 DOI: 10.1038/Onc.2008.356  0.447
2008 Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Research. 68: 5849-58. PMID 18632639 DOI: 10.1158/0008-5472.Can-07-6130  0.471
2008 Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD. The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Research. 68: 4321-30. PMID 18519692 DOI: 10.1158/0008-5472.Can-08-0407  0.446
2008 Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia P, Acevedo-Alvarez M, Lopez-Berestein G. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis : An International Journal On Programmed Cell Death. 13: 915-28. PMID 18491231 DOI: 10.1007/S10495-008-0222-9  0.343
2008 Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 4: 669-79. PMID 18424910 DOI: 10.4161/Auto.6083  0.413
2008 Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2476-83. PMID 18413840 DOI: 10.1158/1078-0432.Ccr-07-4529  0.386
2008 Sood AK, Sanguino A, Lopez-Berestein G. Strategies for in vivo siRNA delivery in cancer Mini-Reviews in Medicinal Chemistry. 8: 248-255. PMID 18336345 DOI: 10.2174/138955708783744074  0.375
2008 Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. Journal of the National Cancer Institute. 100: 359-72. PMID 18314475 DOI: 10.1093/Jnci/Djn024  0.355
2008 Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. Journal of the National Cancer Institute. 100: 109-20. PMID 18182619 DOI: 10.1093/Jnci/Djm279  0.449
2008 Fernandez A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein G. Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target Aacr Education Book. 2008: 589-599. DOI: 10.1158/Aacr.Edb-Can-07-0345  0.336
2008 Armaiz-Pena GN, Mangala LS, Han LY, Lin YG, Schmandt R, Sanguino AM, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. 34. Chronic stress promotes tumor growth through a Src-dependent mechanism in a mouse model of ovarian cancer Brain Behavior and Immunity. 22: 9-10. DOI: 10.1016/J.Bbi.2008.04.035  0.388
2007 Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, ... ... Lopez-Berestein G, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. The Journal of Clinical Investigation. 117: 4044-54. PMID 18060038 DOI: 10.1172/Jci32373  0.323
2007 Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Tae JK, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma Cancer Research. 67: 10976-10983. PMID 18006843 DOI: 10.1158/0008-5472.Can-07-2667  0.451
2007 Landen CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Research. 67: 10389-96. PMID 17974982 DOI: 10.1158/0008-5472.Can-07-0858  0.362
2007 Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism Journal of Biological Chemistry. 282: 29919-29926. PMID 17716980 DOI: 10.1074/Jbc.M611539200  0.354
2007 Ozpolat B, Akar U, Mehta K, Lopez-Berestein G. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy. 3: 480-3. PMID 17507797 DOI: 10.4161/Auto.4349  0.447
2007 Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. International Journal of Pharmaceutics. 341: 221-9. PMID 17499461 DOI: 10.1016/J.Ijpharm.2007.03.043  0.779
2007 Fernández A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein G. Rational drug redesign to overcome drug resistance in cancer therapy: Imatinib moving target Cancer Research. 67: 4028-4033. PMID 17483313 DOI: 10.1158/0008-5472.Can-07-0345  0.336
2007 Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Molecular Cancer Research : McR. 5: 241-9. PMID 17374730 DOI: 10.1158/1541-7786.Mcr-06-0229  0.44
2007 Ozpolat B, Akar U, Zorilla-Calancha I, Vivas-Mejia P, Lopez-Berestein G. Death Associated Protein 5 (DAP5/p97/NAT1) Contributes to Retinoic Acid-Induced Granulocytic Differentiation and Arsenic Trioxide Induced Apotosis through Inhibition of PI3K/Akt/mTOR Pathway in Acute Promyelocytic Leukemia Cells: A Novel Mechanism. Blood. 110: 2836-2836. DOI: 10.1182/Blood.V110.11.2836.2836  0.365
2007 Ozpolat B, Akar U, Colburn NH, Lopez-Berestein G. Novel Tumor Suppressor Protein Programmed Cell Death 4 (PDCD4) Suppresses Activity of PI3K/Akt Pathway and Regulates Expression of p27 (Kip1) and c-myc, DAP5 and Willm’s Tumor (WT1) in Acute Myeloid Leukemia. Blood. 110: 2656-2656. DOI: 10.1182/Blood.V110.11.2656.2656  0.414
2007 Ozpolat B, Akar U, Barria M, Lopez-Berestein G. PKCδ Regulates Retinoic Acid-Induced Myeloid Cell Differentiation through Eukaryotic Initiation Factor Alpha (eIF2α). Blood. 110: 1814-1814. DOI: 10.1182/Blood.V110.11.1814.1814  0.332
2006 Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer Cancer Biology and Therapy. 5: 1708-1713. PMID 17106249 DOI: 10.4161/Cbt.5.12.3468  0.366
2006 Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinasetargeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy Clinical Cancer Research. 12: 4916-4924. PMID 16914580 DOI: 10.1158/1078-0432.Ccr-06-0021  0.377
2006 Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, ... ... Lopez-Berestein G, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nature Medicine. 12: 939-944. PMID 16862152 DOI: 10.1038/Nm1447  0.383
2006 Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 106: 2437-44. PMID 16615096 DOI: 10.1002/Cncr.21854  0.303
2006 Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Therapy. 13: 706-19. PMID 16514421 DOI: 10.1038/sj.cgt.7700945  0.31
2006 Ozpolat B, Akar U, Kondo Y, Lopez-Berestein G. All-Trans-Retinoic Acid (ATRA) Induces Autophagy in Acute Promyelocytic Leukemia Cells. Blood. 108: 2012-2012. DOI: 10.1182/Blood.V108.11.2012.2012  0.374
2006 Akar U, Ozpolat B, Colburn N, Lopez-Berestein G. p38 MAPK Signaling Mediates Retinoic Acid-Induced Expression of a Novel Tumor Suppressor Protein Programmed Cell Death 4 (PDCD4) in Acute Promyelocytic Leukemia Cells. Blood. 108: 1942-1942. DOI: 10.1182/Blood.V108.11.1942.1942  0.396
2006 Ozpolat B, Akar U, Barria M, Lopez-Berestein G. PKCδ Regulates Eukaryotic Initiation Factor eIF2α through PKR during Retinoic Acid-Induced Myeloid Cell Differentiation. Blood. 108: 1928-1928. DOI: 10.1182/Blood.V108.11.1928.1928  0.376
2006 Yang L, Hamilton S, Ellis E, Sanguino A, Lopez-Berestein G, Boyd D. ZNF306, a novel zinc finger transcription factor, drives colon cancer progression – An alternate genetic pathway in tumor progression? European Journal of Cancer Supplements. 4: 6. DOI: 10.1016/J.Ejcsup.2006.04.010  0.38
2006 Sood AK, Thaker PH, Jennings N, Kamat AA, Han LY, Armaiz-Pena G, Lopez-Berestein G, Lutgendorf SK, Cole SW. Tumor cell β adrenergic receptor dependence for chronic stress effects on ovarian cancer growth Brain Behavior and Immunity. 20: 66-67. DOI: 10.1016/J.Bbi.2006.04.149  0.377
2005 Ozpolat B, Mehta K, Lopez-Berestein G. Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells. Leukemia & Lymphoma. 46: 1497-506. PMID 16194896 DOI: 10.1080/10428190500174737  0.312
2004 Ozpolat B, Tari AM, Mehta K, Lopez-Berestein G. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leukemia & Lymphoma. 45: 979-85. PMID 15291358 DOI: 10.1080/1042819031000151833  0.371
2004 Siwak DR, Tari AM, Lopez-Berestein G. Liposomal antisense oligonucleotides for cancer therapy. Methods in Enzymology. 387: 241-53. PMID 15172168 DOI: 10.1016/S0076-6879(04)87015-0  0.376
2004 Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, Mawuenyega KG, Tirado-Gomez M, Lopez-Berestein G, Chen X. Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 104: 1314-23. PMID 15142884 DOI: 10.1182/Blood-2004-01-0046  0.357
2004 Ozpolat B, Tirado-Gomez M, Colburn NH, Lopez-Berestein G. All-trans-Retinoic acid (ATRA) and Arsenic Trioxide-Induced Expression and Regulation of Programmed Cell Death 4 (PDCD4) in Acute Promyelocytic Leukemia. Blood. 104: 886-886. DOI: 10.1182/Blood.V104.11.886.886  0.379
2003 Gutiérrez-Puente Y, Tari AM, Ford RJ, Tamez-Guerra R, Mercado-Hernandez R, Santoyo-Stephano M, Lopez-Berestein G. Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leukemia & Lymphoma. 44: 1979-85. PMID 14738153 DOI: 10.1080/1042819031000099733  0.355
2003 Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. The Journal of Biological Chemistry. 278: 19995-20005. PMID 12644474 DOI: 10.1074/Jbc.M205865200  0.765
2002 Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 21: 5224-32. PMID 12149644 DOI: 10.1038/Sj.Onc.1205660  0.425
2002 Gutiérrez-Puente Y, Zapata-Benavides P, Tari AM, López-Berestein G. Bcl-2-related antisense therapy. Seminars in Oncology. 29: 71-6. PMID 12138400 DOI: 10.1053/sonc.2002.34058  0.344
2002 Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM. Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochemical and Biophysical Research Communications. 295: 784-90. PMID 12127961 DOI: 10.1016/S0006-291X(02)00751-9  0.416
2002 Ozpolat B, Mehta K, Tari AM, Lopez-Berestein G. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. American Journal of Hematology. 70: 39-47. PMID 11994980 DOI: 10.1002/Ajh.10099  0.343
2002 Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 99: 3461-4. PMID 11964319 DOI: 10.1182/Blood.V99.9.3461  0.334
2001 Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, ... ... Lopez-Berestein G, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial Journal of Clinical Oncology. 19: 3422-3433. PMID 11454891 DOI: 10.1200/Jco.2001.19.14.3422  0.411
2000 Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene. 19: 6271-6. PMID 11175341 DOI: 10.1038/Sj.Onc.1204014  0.394
2000 Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins Blood. 95: 3929-3938. DOI: 10.1182/Blood.V95.12.3929  0.351
1999 Tari AM, Hung MC, Li K, Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 18: 1325-32. PMID 10022814 DOI: 10.1038/Sj.Onc.1202422  0.401
1999 Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung M-. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncology Reports. 6: 257-262. DOI: 10.3892/Or.6.2.257  0.327
1998 Hortobagyi GN, Hung MC, Lopez-Berestein G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Human Gene Therapy. 9: 1775-98. PMID 9721088 DOI: 10.1089/HUM.1998.9.12-1775  0.31
1998 Tormo M, Tari AM, McDonnell TJ, Cabanillas F, Garcia-Conde J, Lopez-Berestein G. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leukemia & Lymphoma. 30: 367-79. PMID 9713967 DOI: 10.3109/10428199809057548  0.339
1997 Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 15: 2767-72. PMID 9419967 DOI: 10.1038/Sj.Onc.1201464  0.312
1997 Tari AM, Arlinghaus R, Lopez-Berestein G. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochemical and Biophysical Research Communications. 235: 383-8. PMID 9199202 DOI: 10.1006/Bbrc.1997.6791  0.34
1997 Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, Hung MC. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Therapy. 4: 238-43. PMID 9135737 DOI: 10.1038/Sj.Gt.3300376  0.313
1997 Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leukemia & Lymphoma. 21: 93-7. PMID 8907275 DOI: 10.3109/10428199609067585  0.355
1997 Tari AM, Lopez-Berestein G. Oligonucleotide Therapy for Hematological Malignancies Journal of Liposome Research. 7: 19-30. DOI: 10.3109/08982109709035479  0.327
1996 Vadiei K, Tucker SD, Lopez-Berestein G, Wasan KM. Nephroprotective mechanism(s) of pentoxifylline: Reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release Pharmacology and Toxicology. 78: 174-180. PMID 8882351 DOI: 10.1111/J.1600-0773.1996.Tb00200.X  0.301
1994 Tari A, Tucker S, Deisseroth A, Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia [see comments] Blood. 84: 601-607. DOI: 10.1182/Blood.V84.2.601.Bloodjournal842601  0.338
1984 Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochimica Et Biophysica Acta. 770: 230-4. PMID 6696909 DOI: 10.1016/0005-2736(84)90135-4  0.303
1984 Lopez-Berestein G, Milas L, Hunter N, Mehta K, Hersh EM, Kurahara CG, Vandupas M, Eppstein DA. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine. Clinical & Experimental Metastasis. 2: 127-37. PMID 6543694 DOI: 10.1007/Bf00052413  0.312
Show low-probability matches.